NCT03553433

Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis

A Phase 4 Multicenter, Randomized, Placebo-controlled Study Evaluating the Effect of Apremilast on Pruritus and Quality of Life of Patients With Moderate-to-severe Scalp Psoriasis

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 90 (estimated)
• Sponsor: University of Zurich · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A phase 4 multicenter, randomized, placebo-controlled Study evaluating the Effect of Apremilast on Pruritus and Quality of Life of Patients with moderate-to-severe Scalp Psoriasis

Detailed description

The scalp is the most frequently affected body region in psoriasis. Scalp Psoriasis can impair the quality of life greatly due to pruritus. This is however not usually investigated as a primary outcome of treatments. This study will investigate the effects of apremilast on the pruritus and quality of life and other patient reported outcomes in patients with scalp psoriasis.

Conditions

• Psoriasis of Scalp
• Psoriasis Vulgaris

Interventions

Type	Name	Description
DRUG	Apremilast 30mg	Anti-psoriatic drug
DRUG	Placebo Oral Tablet	Indistinguishable tablets not containing apremilast, Placebo Oral Tablet

Timeline

• Start date: 2018-06-01
• Primary completion: 2019-12-01
• Completion: 2020-06-01
• First posted: 2018-06-12
• Last updated: 2018-06-12

Locations

4 sites across 1 country: Switzerland